<div class="white-sheet">
	<div class="content-slide">

		<div class="title-bar red"></div>

		<div class="wrapper slide-2-6-2-6">

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>		
			</div>

			<div class="slide-title red">
				Treatment of refractory severe aplastic anaemia
			</div>


			<div class="content-container">
				
				<div class="content-left">
					<ul>
						<li><span>Refractory aplastic anaemia is defined as lack of response with persistence of severe pancytopenia at 6 months after one course of IST<sup>1</sup></span>
							<ul>
								<li><span>Approximately one-third of patients with severe aplastic anaemia fail to respond to IST<sup>2</sup></span></li>
							</ul>
						</li>
						<li><span>HSCT should be considered if pancytopenia persists 6 months after IST<sup>3</sup></span>
							<ul>
								<li><span>First choice in older and younger patients: matched sibling donor HSCT<sup>3</sup></span></li>
								<li><span>Unrelated donor (UD) HSCT may be considered in younger patients<sup>3</sup></span></li>
							</ul>
						</li>
						<li><span>Survival rates have improved over time<sup>4</sup></span></li>
					</ul>
				</div>


				<div class="content-right">
					<div class="red-label">Five-year survival of patients with IST-refractory severe<br /> aplastic anaemia has improved over time, but is still<br /> below that observed for HSCT<sup>4</sup></div>
					
						<img src="media/images/slide_2-6-2-6/picture1.png" alt="">

						<p class="small-print">Group 1: patients treated from 1989 to 1996; Group 2: patients treated from 1996 to 2002; Group 3: patients treated from 2002 to 2008</p>
					
				</div>


			</div>

		</div>

		<div class="information-overlay overlay">
			
			<header>Aplastic anaemia is a consequence of bone marrow failure</header>

			<ul>
				<li><span>Treatment approach will depend on factors including the patient’s age and the availability of a histocompatible donor<sup>3</sup></span></li>
				<li><span>A second course of IST may be preferable to a high-risk transplant from a mismatched,<sup>5</sup> unrelated,<sup>5</sup> haploidentical<sup>7</sup> or umbilical cord donor<sup>7</sup></span>
					<ul>
						<li><span>Response to r-ATG may be 27–77%<sup>8,9</sup></span></li>
					</ul>
				</li>
				<li><span>Alemtuzumab has also been investigated for use in refractory severe aplastic anaemia, with a response rate of 37% (compared with 33% for r-ATG)<sup>10</sup></span></li>
				<li><span>Before the advent of bone-marrow transplantation and IST in the 1970s, aplastic anaemia was fatal in most cases within a year of diagnosis<sup>11</sup></span>
					<ul>
						<li><span>Survival following haematopoietic stem cell transplantation may be as high as 80% if a matched sibling donor can be found<sup>12</sup></span></li>
					</ul>
				</li>
				<li><span>Data suggests that survival following IST has not improved to the same degree as haematopoietic stem cell transplantation<sup>13</sup></span>
					<ul>
						<li><span>This may be cause IST regimens have not changed over time<sup>13</sup></span></li>
						<li><span>Observable improvements may be attributed to better antimicrobial support, which has reduced infection-related mortality<sup>14</sup></span></li>
					</ul>
				</li>
			</ul>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ol>
				<li class="navigateHref" data-navtarget="media/documents/Pallister&Watson-2011-Haematology-v2p27-35.pdf"><span>Marsh JWC & Kulasekararaj AG. <i>Blood</i> 2013;122:3561</span></li>
				<li class="navigateHref" data-navtarget="media/documents/JanewayC-2001-Immunobiology-v9-Humoral Immunity.pdf"><span>Young NS <i>et al. Blood</i> 2006;108:2509</span></li>
				<li class="navigateHref" data-navtarget="media/documents/JanewayC-2001-Immunobiology-v9-Humoral Immunity.pdf"><span>Scheinberg P. <i>Hematology Am Soc Hematol Educ Program</i> 2012;292</span></li>
				<li class="navigateHref" data-navtarget="media/documents/JanewayC-2001-Immunobiology-v9-Humoral Immunity.pdf"><span>Valdez JM <i>et al. Clin Infect Dis</i> 2011;52:726</span></li>
				<li class="navigateHref" data-navtarget="media/documents/JanewayC-2001-Immunobiology-v9-Humoral Immunity.pdf"><span>Passweg JR <i>et al. Bone Marrow Transplant</i> 2006;37:641</span></li>
				<li class="navigateHref" data-navtarget="media/documents/JanewayC-2001-Immunobiology-v9-Humoral Immunity.pdf"><span>Perez-Albuerne ED <i>et al. Br J Haematol</i> 2008;141:216</span></li>
				<li class="navigateHref" data-navtarget="media/documents/JanewayC-2001-Immunobiology-v9-Humoral Immunity.pdf"><span>Liu H-L <i>et al. Bone Marrow Transplant</i> 2012;47:1186</span></li>
				<li class="navigateHref" data-navtarget="media/documents/JanewayC-2001-Immunobiology-v9-Humoral Immunity.pdf"><span>Scheinberg P <i>et al. Br J Haematol</i> 2006;133:622</span></li>
				<li class="navigateHref" data-navtarget="media/documents/JanewayC-2001-Immunobiology-v9-Humoral Immunity.pdf"><span>Di Bona E <i>et al. Br J Haematol</i> 199;107:330</span></li>
				<li class="navigateHref" data-navtarget="media/documents/JanewayC-2001-Immunobiology-v9-Humoral Immunity.pdf"><span>Scheinberg P <i>et al. Blood</i> 2012;119:345</span></li>
				<li class="navigateHref" data-navtarget="media/documents/JanewayC-2001-Immunobiology-v9-Humoral Immunity.pdf"><span>Brodsky RA & Jones RJ. <i>Lancet</i> 2005;365:1647</span></li>
				<li class="navigateHref" data-navtarget="media/documents/JanewayC-2001-Immunobiology-v9-Humoral Immunity.pdf"><span>Gupta V <i>et al. Haematologica</i> 2010;95:2119</span></li>
				<li class="navigateHref" data-navtarget="media/documents/JanewayC-2001-Immunobiology-v9-Humoral Immunity.pdf"><span>Locasciulli A <i>et al. Haematologica</i> 2007;92:11</span></li>
				<li class="navigateHref" data-navtarget="media/documents/JanewayC-2001-Immunobiology-v9-Humoral Immunity.pdf"><span>Valdez JM <i>et al. Clin Infect Dis</i> 2011;52:726</span></li>
			</ol>

		</div>

	</div>
</div>